This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.
For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Buenos Aires, Argentina
CABA, Argentina
CABA, Argentina
Mar del Plata, Argentina